Australian Machinery Stock News

Cochlear (ASX:COH) has reported its H1 2026 results with trailing twelve month revenue of A$2.3b and basic EPS of A$5.28, giving investors a clear read on both top line scale and earnings power. The company has seen half year revenue move from A$1,137.1 million in H2 2024 to A$1,171.8 million in H1 2025 and A$1,171.3 million in H2 2025, while basic EPS shifted from A$2.53 to A$3.13 and then A$2.81 over the same periods. This sets the backdrop for a margin story that investors will parse...

In recent days, Technology One reported that 30,270 options and 3,800 performance rights had lapsed after their performance or service conditions were not met, slightly trimming potential future share issuance with little impact on the overall capital structure. At the same time, Technology One has appeared on an ASX downtrends list in technical trading scans, a development that may influence investor sentiment more than the relatively minor equity incentive lapses. We’ll now examine how...

Nick Scali (ASX:NCK) has released its H1 2026 scorecard, with investors already eyeing how the latest numbers fit into the broader trend in revenue and EPS. The company has seen half year revenue move from A$241.6 million in H2 2024 to A$251.1 million in H1 2025 and then A$244.2 million in H2 2025, while basic EPS shifted from A$0.457 to A$0.351 and then A$0.324 over the same periods. This gives investors a clear view of how recent trading has flowed through to the bottom line. With net...

Boab Metals (ASX:BML) has moved into focus after securing final works approvals for full construction at its Sorby Hills silver, lead and zinc project, marking a key step toward potential future production. See our latest analysis for Boab Metals. Those approvals and recent capital moves, including a A$60m follow on equity offering at A$0.40 and new director shares tied to Sorby Hills permits, come after strong momentum. The company has recorded a 90 day share price return of 52.38% and a...

In the past quarter, James Hardie Industries plc reported third-quarter 2025 sales of US$1,239.8 million, up from US$953.3 million a year earlier, while net income fell to US$68.7 million from US$141.7 million and basic earnings per share from continuing operations declined to US$0.12 from US$0.33. Despite the weaker headline profit, the company exceeded analyst expectations for adjusted earnings and revenue, highlighting strong sales growth supported by the early benefits of its AZEK...

ANZ Group Holdings (ASX:ANZ) is back in focus after revealing first quarter costs came in lower than analysts had expected, a surprise that has sharpened attention on the bank’s efficiency and profit potential. See our latest analysis for ANZ Group Holdings. The cost surprise has arrived on top of strong recent momentum, with ANZ’s 7 day share price return of 10.48% and 30 day share price return of 12.40% adding to a 1 year total shareholder return of 37.44%. This suggests sentiment has been...

G8 Education recently announced a large A$350,000,000 non-cash goodwill impairment for FY25, alongside suspending its final dividend and pausing its on-market share buyback in response to weaker sector conditions and softer earnings expectations. Despite these conservative capital measures, the company has reaffirmed its FY25 EBIT guidance, underscoring management’s view that underlying operations remain broadly stable even as accounting values are reset. We’ll now examine how this sizeable...

MFF Capital Investments (ASX:MFF) has released its H1 2026 scorecard, with recent half-year figures showing H2 2025 revenue of A$68.5 million and basic EPS of A$0.09, alongside H1 2025 revenue of A$562.9 million and basic EPS of A$0.66. These are set against H2 2024 revenue of A$449.6 million and basic EPS of A$0.52. The company has also reported trailing 12‑month revenue of A$631.4 million with basic EPS of A$0.74 in H2 2025 and A$1.18 on A$1.0 billion of revenue in H1 2025, giving investors...

In February 2026, Mesoblast reported data from patients treated under the U.S. Emergency Investigational New Drug program showing that its FDA-approved cell therapy Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease across children and adults, at different treatment lines and regardless of ruxolitinib use or resistance. The findings, which highlighted better completion of treatment and survival when Ryoncil was used...

Insurance Australia Group (ASX:IAG) has put up another set of solid headline numbers for H1 2026, with trailing twelve month revenue of about A$17.4b and basic EPS of A$0.57 coming off net income of A$1,359m, while the latest reported half in 2025 delivered revenue of A$8.7b and EPS of A$0.25 on net income of A$581m. Over the past few reported halves the company has seen revenue move from A$8.1b in H2 2024 to A$8.7b in H1 2025 and A$8.7b in H2 2025, alongside EPS shifting from A$0.21 to...

Oneview Healthcare (ASX:ONE) has put fresh numbers on the table for FY 2025, reporting first half revenue of €6.3 million and a basic EPS loss of €0.01. Trailing twelve month revenue stands at €11.6 million with a basic EPS loss of €0.016452. Over recent periods the company’s revenue has moved from €4.7 million in the first half of 2024 to €5.2 million in the second half of 2024 and then to €6.3 million in the first half of 2025. Across the same periods, half year basic EPS figures have...

CAR Group (ASX:CAR) is back in focus after its latest half year earnings, where revenue reached A$625.79 million and net profit came in at A$143.34 million, alongside a higher interim dividend. See our latest analysis for CAR Group. Despite the solid half year update and higher dividend, the share price has had a tougher run, with a 30 day share price return of a 17.67% decline and a year to date share price return of an 18.79% decline. The 1 year total shareholder return of a 32.67% decline...

Northern Star Resources (ASX:NST) has reported another solid set of numbers for H1 2026, with the latest reported half year in H2 2025 showing revenue of A$3.5b and basic EPS of A$0.68, underpinned by net income of A$833.3m. The company has seen revenue move from A$2.7b and EPS of A$0.38 in H2 2024 to A$2.9b and EPS of A$0.44 in H1 2025, then to A$3.5b and EPS of A$0.68 in H2 2025. This sets up a trailing twelve month net income of A$1.5b and EPS of A$1.16. With net profit margins running at...

In early 2026, Electro Optic Systems (EOS) issued a detailed rebuttal to US short seller Grizzly Research’s report, clarifying its cash position, explaining that a disputed US$80 million South Korean high‑energy laser contract is conditional and excluded from its confirmed A$459 million order backlog, and defending the MARSS Group acquisition. At the same time, EOS signed a collaboration agreement with Turkish defence company ROKETSAN and disclosed a conditional high‑energy laser contract in...

Pro Medicus (ASX:PME) has just posted its H1 2026 scorecard, headlined by trailing 12 month revenue of A$241.1 million alongside basic EPS of A$2.25, as the company continues to convert its imaging software footprint into solid top and bottom line figures. The company has seen revenue move from A$184.6 million to A$241.1 million across recent trailing 12 month periods, with basic EPS stepping up from A$0.94 to A$2.25 over the same horizon. Reported net profit margin has shifted sharply higher...

AMP (ASX:AMP) has put fresh numbers on the table for FY 2025, reporting first half revenue of A$1.4 billion and basic EPS of A$0.039. This helps set the tone for how the year is shaping up after a mixed FY 2024. The company reported revenue of A$1.4 billion in the first half of 2024 and a loss of A$392 million in the second half. Over the same period, basic EPS moved from A$0.0387 to A$0.0185, before reaching A$0.039 in the latest half. For investors, a key focus now is how these results...

Commonwealth Bank of Australia has reported higher half‑year earnings to 31 December 2025, with net income rising to A$5,367 million and basic earnings per share from continuing operations lifting to A$3.237, and it has declared a fully franked interim dividend of A$2.35 per share payable on 30 March 2026. By combining record cash earnings with an increased fully franked dividend and continued investment in technology and AI, the bank is signalling confidence in its core franchise strength...

What triggered the latest move in Deep Yellow shares? Deep Yellow (ASX:DYL) has been in focus after confirming uranium mineralisation at the S Bend prospect near its Tumas Project, as well as announcing that Managing Director and CEO John Borshoff will step down immediately. See our latest analysis for Deep Yellow. At the current share price of A$2.47, Deep Yellow has seen a 22.89% 1 month share price return and a 54.86% 3 month share price return. Its 1 year total shareholder return of...

Insiders who purchased Canadian Phosphate Limited ( ASX:CP8 ) shares in the past 12 months are unlikely to be deeply...

Neuren Pharmaceuticals (ASX:NEU) has announced a new share buy-back program, authorising repurchases of up to 6,350,631 shares, or 5% of its issued capital, through to March 2027. See our latest analysis for Neuren Pharmaceuticals. The buy-back comes after a sharp 30 day share price return of around a 30% decline and a 90 day share price return of about a 29% decline, even though the 1 year and multi year total shareholder returns remain positive and very strong. This suggests recent selling...

The Australian market has been experiencing a turbulent period, with concerns over artificial intelligence and tech sector volatility affecting investor sentiment. Despite these challenges, investors continue to seek opportunities in various sectors, including penny stocks. While the term 'penny stock' might feel outdated, it remains relevant as these smaller or newer companies can offer affordability and growth potential when backed by solid financials. Let's explore three ASX penny stocks...

Why CSL (ASX:CSL) is in focus right now CSL (ASX:CSL) is back in the spotlight after reporting an 81% drop in first half net profit, confirming its interim dividend, expanding its share buyback program, and announcing the sudden retirement of CEO Paul McKenzie. See our latest analysis for CSL. Those profit and leadership shocks have gone hand in hand with sharp share price moves, with a 1 day share price return of 6.88% decline and a 7 day share price return of 16.03% decline. The 1 year...

If you are wondering whether Woolworths Group is fairly priced or offering value right now, you are not alone. This article is all about unpacking what the current share price really reflects. The stock recently closed at A$32.21, with returns of 1.9% over 7 days, 6.8% over 30 days, 9.4% year to date, 9.6% over 1 year, and 12.8% over 5 years, while the 3 year return sits at a 2.6% decline. Recent news around Woolworths Group has focused on its position as one of Australia's largest consumer...

REA Group (ASX:REA) has put shareholder returns in focus after its latest half year earnings, pairing a higher ordinary dividend with Board approval for a share repurchase program of up to A$200 million. See our latest analysis for REA Group. Despite the buyback and higher dividend, REA Group’s recent share price return has been weak, with a 1-month share price return decline of 11.12% and a 1-year total shareholder return decline of 37.53%, while longer term total shareholder returns over 3...